Opendata, web and dolomites

NEXTER SIGNED

Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEXTER project word cloud

Explore the words cloud of the NEXTER project. It provides you a very rough idea of what is the project "NEXTER" about.

biosynthesis    distinction    antibiotics    antibiotic    bacterial    amr    perfecting    desperately    plan    environment    pseudomonas    global    technological    partnership    company    stop    spread    shown    capacity    pathogens    drug    negligible    protecting    commercialize    efforts    poc    species    companies    beneficial    structural    selectivity    mechanisms    designed    strategy    contamination    antimicrobial    environmental    lower    enterococcus    unpredictable    ip    pathogen    strains    commercialization    strategic    resistance    cells    decrease    causing    drugs    medicine    strengthen    hence    alongside    modern    pharmaceuticals    innovative    selective    prevent    powerful    emergence    human    escape    rapid    motifs    preserve    pathogenic    outcome    resistant    inhibit    additional    designing    degradable    compounds    synthetic    discovered    least    bacteria    clinically    attempt    network    aureus    ribosomal    revolutionary    attaching    ribosome    moieties    microbiome    primary    pharma    dozes    contaminate    delivered    health    chemical    protein    harm   

Project "NEXTER" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

The rapid emergence and spread of Multi-drug Antimicrobial Resistance (AMR), alongside the negligible efforts of the major pharmaceuticals companies in the development of new antibiotics, result in a major global concern of modern medicine. Moreover, the currently clinically used antibiotics contaminate the environment and may harm the human microbiome, causing unpredictable health concerns. We discovered that by targeting species-specific ribosome unique structural motifs, identified by us, using our designed degradable novel synthetic lead compounds, it is possible to inhibit protein biosynthesis in bacteria. Our approach should enable distinction between pathogenic and non-pathogenic bacteria and between bacterial and human ribosome. This drug selectivity should decrease resistance, preserve the beneficial microbiome and allow usage of lower antibiotics dozes. Furthermore, the designed degradable lead compounds should prevent additional environmental contamination. Hence, our approach allows designing innovative powerful selective antibiotics that escape the existing resistance mechanisms. Several of the primary designed compounds shown to stop the growth of the multi-resistant S. aureus human pathogen were delivered into the bacterial cells by attaching specific chemical moieties to them. In this PoC we plan to design similar compounds for other human pathogens, such as Enterococcus and Pseudomonas species, where revolutionary effective antibiotic drugs against their resistant strains is desperately needed. In addition to the technological PoC in this project, we will attempt pre-commercialization studies aiming at perfecting the commercialization strategy, protecting the IP and strengthen the network for best possible commercialization outcome. The general objective is to establish at least one strategic partnership with a pharma company which has the capacity to further test, develop and commercialize antibiotics that exploit ribosomal novel unique targets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEXTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More